{"brief_title": "A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes", "brief_summary": "The primary objective of the study is to determine the efficacy of thalidomide for the treatment of anemia in patients with myelodysplastic syndromes (MDS).", "condition": "Myelodysplastic Syndromes", "intervention_type": "Drug", "intervention_name": "thalidomide", "criteria": "- Eligible patients must have a diagnosis of myelodysplastic syndrome - Life expectancy of at least 6 months. - Patients must be able to adhere to the study visit schedule and other protocol requirements. - Patients must understand and voluntarily sign an informed consent document. - Women of childbearing potential (WCBP) must agree to practice abstinence or to use TWO methods of contraception beginning 4 weeks prior to the start of study medication and throughout the course of treatment. - Males must use barrier contraception when engaging in reproductive sexual activity with women of childbearing potential.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "80 Years", "healthy_volunteers": "No", "id": "NCT00050843.xml"}